Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Glycosylated analogues of novobiocin, discovered using a broad library of enzymes, have 100-fold improved activity against breast, brain, pancreatic, lung and ovarian cancers and ablated associated off-target activity leading to an up to 2.7 × 10(4) fold increase in selectivity.

Original publication

DOI

10.1039/c1cc13552j

Type

Journal article

Journal

Chem Commun (Camb)

Publication Date

14/10/2011

Volume

47

Pages

10569 - 10571

Keywords

Cell Line, Tumor, DNA Topoisomerases, Type II, Drug Screening Assays, Antitumor, Enzyme Inhibitors, Enzymes, Glycosylation, HSP90 Heat-Shock Proteins, Humans, Novobiocin